

# Genetic variants in calcium calmodulin pathway in association with cardiovascular disease

Citation for published version (APA):

Beghi, S. (2022). *Genetic variants in calcium calmodulin pathway in association with cardiovascular disease: focus on the potential role of CaMKK1 in heart and vessels*. [Doctoral Thesis, Maastricht University, University of Parma]. Maastricht University. <https://doi.org/10.26481/dis.20220523sb>

## Document status and date:

Published: 01/01/2022

## DOI:

[10.26481/dis.20220523sb](https://doi.org/10.26481/dis.20220523sb)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## **ABSTRACT**

Cardiovascular disease (CVD) is the leading cause of death all over the world and it affects an increasing number of people annually. Numerous risk factors are involved in the etiology of this complex disease. In addition to an unhealthy lifestyle, environmental factors, and other comorbidities, genetics also plays a role. The study of genetic variants associated with CVD is one of the main areas of interest nowadays. This is because it can aid in the identification of genetic biomarkers for prevention, prediction and treatment of patients affected by CVD.

Regulation of calcium signalling through calmodulin (CaM) is a key pathway involved in the physiology and molecular biology of the heart. CaM binds calcium and regulates calcium, playing a crucial role in several processes, such as cellular excitation-contraction coupling.

Research has shown that genetic variants, such as polymorphisms, can be factors predisposing to complex diseases. Thus, I hypothesized that studying and characterizing polymorphisms in the components of the CaM pathway could unravel how genetic traits influence CVD predispositions. In this thesis I focused on polymorphisms in 3 isoforms of CaM (CaM1, 2, 3) and proteins involved in its signalling, NOS (nitric oxide synthases) and CaMKs (calcium/calmodulin dependent protein kinases), in CVD. The analysis of the polymorphisms was performed on a cohort of 300 cardiopathic patients; a blood sample was collected and spotted on FTA cards. DNA was isolated and RLFP-PCR was performed in order to analyse the single nucleotide polymorphisms (SNP) of interest.

The comparison of the genetic and allelic frequencies between the group of interest and the European reference group, used as control, showed interesting results in increasing the risk to develop a specific CVD, specifically for the SNP rs1549758, rs61202009 in NOS3 and mainly for the SNP rs7214723 in CaMKK1. The significant and interesting results of this last SNP in the cardiopathic Italian population, I analysed it also in a dutch cohort population and carried out an in-depth study of the role of CaMKK1 (calcium calmodulin–dependent protein kinase kinase I) in the heart and blood vessels, through in vitro studies on human vascular smooth muscle cells. In this in vitro experiment I found that CaMKK1 is a novel regulator of phenotypic switching of hVSMC towards synthetic VSMCs, thereby providing CaMKK1 as a new therapeutic target to reduce vascular remodeling, as well as a new potential genetic biomarker in the contest of cardiovascular diseases.